Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 289-290, 2005; 10.1373/clinchem.2004.044016
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, B. B.
Right arrow Articles by Mandell, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, B. B.
Right arrow Articles by Mandell, J. W.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Clinical Immunology
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2005;51:289-290.)
© 2005 American Association for Clinical Chemistry, Inc.

Editorials

Multiplex Method for Measuring Biomarkers of Alzheimer Disease in Cerebrospinal Fluid

Bradley B. Miller1,2 and James W. Mandell1,a

Departments of1 Pathology (Neuropathology) and2 Neurology, University of Virginia Health System Charlottesville, VA

aAddress correspondence to this author at: Department of Pathology (Neuropathology), University of Virginia Health System, Charlottesville, VA, 22908. Fax 434-924-9177; e-mail jwm2m@virginia.edu.

The first 20% of the full text of this article appears below.

Alzheimer disease (AD), the most common form of dementia, is a neurodegenerative disorder characterized by neuronal and synaptic loss. Despite its high prevalence and great cost to society, there is no definitive premortem test for AD (1)(2). The diagnosis of probable or possible AD is based on a history of insidious onset and progressive impairment of memory as well as loss of other cognitive functions (3). The most important clinical task is the exclusion of reversible causes of dementia, most commonly vascular dementia. It is of little comfort to treating physicians and family members that postmortem examination of the brain by the pathologist is the only reliable diagnostic test for AD. Typically, microscopic examination of stained sections of brain taken from cortical and limbic brain regions reveals the hallmark changes of AD, namely, accumulation of intracellular neurofibrillary tangles and extracellular amyloid plaques. Neurofibrillary tangles are composed mainly of abnormally hyperphosphorylated tau protein (P-TAU). The extracellular amyloid plaques are composed of the 40- and 42-amino acid-long ß-amyloid peptides [Aß(1–40) and Aß(1–42)]. Several neuropathologic subtypes of AD have been described, depending principally on the cortical regions most affected by neuronal loss, and the . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.